Setor K Kunutsor1, Stephan J L Bakker2, Ronald T Gansevoort2, Rajiv Chowdhury2, Robin P F Dullaart2. 1. From the Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom (S.K.K., R.C.); Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom (S.K.K.); Departments of Nephrology Medicine (S.J.L.B., R.T.G.) and Endocrinology (R.P.F.D.), University of Groningen and University Medical Center, Groningen, The Netherlands. skk31@cantab.net. 2. From the Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom (S.K.K., R.C.); Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom (S.K.K.); Departments of Nephrology Medicine (S.J.L.B., R.T.G.) and Endocrinology (R.P.F.D.), University of Groningen and University Medical Center, Groningen, The Netherlands.
Abstract
OBJECTIVE: To assess the association of circulating total bilirubin and cardiovascular disease (CVD) risk in a new prospective study and to determine whether adding information on total bilirubin values to established cardiovascular risk factors is associated with improvement in prediction of CVD risk. APPROACH AND RESULTS: Circulating total bilirubin levels were measured at baseline in the PREVEND (Prevention of Renal and Vascular End-stage Disease) prospective study of 7222 participants and 773 incident CVD events. Total bilirubin was log-linearly associated with CVD risk. Age- and sex-adjusted hazard ratio (95% confidence interval) for CVD per 1-SD increase in loge total bilirubin was 0.82 (0.76 to 0.88; P<0.001), which was minimally attenuated to 0.89 (0.82 to 0.96; P=0.003) after further adjustment for established risk factors. In a meta-analysis of 12 population-based prospective studies involving 9378 incident CVD cases, the pooled multivariate-adjusted relative risk (95% confidence interval) for CVD was 0.93 (0.90 to 0.97; P<0.001) per 1-SD increase in total bilirubin levels. The corresponding pooled risks for coronary heart disease and stroke were 0.95 (0.92 to 0.99; P=0.018) and 0.93 (0.88 to 0.98; P=0.006), respectively. Addition of information on total bilirubin to a CVD risk prediction model containing established risk factors was associated with a C-index change of 0.0013 (-0.0004 to 0.0029; P=0.13). CONCLUSIONS: There is a log-linear inverse association between circulating total bilirubin level and CVD risk, which is independent of established risk factors. Nonetheless, inclusion of total bilirubin in the standard established risk factors panel provides no significant improvement in CVD risk prediction.
OBJECTIVE: To assess the association of circulating total bilirubin and cardiovascular disease (CVD) risk in a new prospective study and to determine whether adding information on total bilirubin values to established cardiovascular risk factors is associated with improvement in prediction of CVD risk. APPROACH AND RESULTS: Circulating total bilirubin levels were measured at baseline in the PREVEND (Prevention of Renal and Vascular End-stage Disease) prospective study of 7222 participants and 773 incident CVD events. Total bilirubin was log-linearly associated with CVD risk. Age- and sex-adjusted hazard ratio (95% confidence interval) for CVD per 1-SD increase in loge total bilirubin was 0.82 (0.76 to 0.88; P<0.001), which was minimally attenuated to 0.89 (0.82 to 0.96; P=0.003) after further adjustment for established risk factors. In a meta-analysis of 12 population-based prospective studies involving 9378 incident CVD cases, the pooled multivariate-adjusted relative risk (95% confidence interval) for CVD was 0.93 (0.90 to 0.97; P<0.001) per 1-SD increase in total bilirubin levels. The corresponding pooled risks for coronary heart disease and stroke were 0.95 (0.92 to 0.99; P=0.018) and 0.93 (0.88 to 0.98; P=0.006), respectively. Addition of information on total bilirubin to a CVD risk prediction model containing established risk factors was associated with a C-index change of 0.0013 (-0.0004 to 0.0029; P=0.13). CONCLUSIONS: There is a log-linear inverse association between circulating total bilirubin level and CVD risk, which is independent of established risk factors. Nonetheless, inclusion of total bilirubin in the standard established risk factors panel provides no significant improvement in CVD risk prediction.
Authors: Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Guoqing Yin; Lu Liu; Abdul-Quddus Mohammed; Rong Jiang; Fuad A Abdu; Wenliang Che Journal: Int J Med Sci Date: 2022-05-27 Impact factor: 3.642
Authors: Katherine H Shutta; Raji Balasubramanian; Tianyi Huang; Shaili C Jha; Oana A Zeleznik; Candyce H Kroenke; Lesley F Tinker; Jordan W Smoller; Ramon Casanova; Shelley S Tworoger; JoAnn E Manson; Clary B Clish; Kathryn M Rexrode; Susan E Hankinson; Laura D Kubzansky Journal: Psychoneuroendocrinology Date: 2021-09-20 Impact factor: 4.693
Authors: Jacy T Zanussi; Juan Zhao; Chad A Dorn; Ge Liu; QiPing Feng; WeiQi Wei; Jonathan D Mosley; C Michael Stein; Vivian K Kawai Journal: Clin Pharmacol Ther Date: 2021-10-24 Impact factor: 6.903
Authors: Chaudry N Majeed; Muhammad I Ahmad; Irfan Ahsan; Muhammad A Anees; Sanjay K Maheshwari; Elsayed Z Soliman Journal: Ann Noninvasive Electrocardiol Date: 2019-09-09 Impact factor: 1.468
Authors: Tianyi Huang; Oana A Zeleznik; Elizabeth M Poole; Clary B Clish; Amy A Deik; Justin M Scott; Céline Vetter; Eva S Schernhammer; Robert Brunner; Lauren Hale; JoAnn E Manson; Frank B Hu; Susan Redline; Shelley S Tworoger; Kathryn M Rexrode Journal: Int J Epidemiol Date: 2019-08-01 Impact factor: 7.196
Authors: Yi Yang; Jun Wang; A Ji Gu Li Wai Si Ding; Yanan Xu; Haibing Jiang; Kezhong Ma; Tongjian Zhu Journal: BMC Cardiovasc Disord Date: 2022-04-12 Impact factor: 2.298